Clinical Trial

Long-Acting Naltrexone for Pre-Release Prisoners

Study Description

Long-acting Naltrexone for Pre-release Prisoners

This proposed five-year study will focus on whether the addition of providing XR-NTX treatment at a patients' place of residence will increase adherence and thus efficacy of the medication.Following initial screening, informed consent, and medical examination, pre-release prisoners at each facility will be block randomized (N=240) within gender to either: Condition 1. XR-NTX-OTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at an opioid treatment program; or Condition 2. XR-NTX+MMTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at the patient's place of residence.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - XR-NTX

Vivitrol

place of residence

One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence

opioid treatment program

One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program

Additional Information

Official Study Title

Long-acting Naltrexone for Pre-release Prisoners: A Randomized Trial of Mobile Treatment

Clinical Trial ID

NCT02867124

ParticipAid ID

9av55e